Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy.

Perspectives in Medicinal Chemistry
Mona DarwishJohn Messina

Abstract

The treatment of breakthrough pain (BTP), a transitory exacerbation of pain that occurs on a background of otherwise-controlled, persistent pain, requires an opioid formulation and/or method of administration that can provide rapid and extensive systemic exposure. Fentanyl buccal tablet (FBT; FENTORA((R)), Cephalon, Inc.) employs OraVescent((R)) drug delivery technology, which enhances the rate and extent of fentanyl absorption. OraVescent technology enhances the oral dissolution and buccal absorption of fentanyl, which facilitates rapid uptake of fentanyl into the bloodstream, reducing gastrointestinal absorption and minimizing extensive first-pass metabolism. The resulting pharmacokinetic profile of FBT is characterized by greater bioavailability and a higher early systemic exposure compared with the earlier oral transmucosal fentanyl citrate formulation. In clinical studies of opioid-tolerant patients with cancer-related and noncancer-related BTP, FBT has provided consistent and clinically relevant improvements in pain intensity and pain relief relative to placebo, with a safety and tolerability profile that is generally typical of that observed with other potent opioids. The pharmacokinetic properties of FBT allow for meani...Continue Reading

References

Jun 1, 1990·Pain·R K Portenoy, N A Hagen
Aug 1, 1991·Anesthesiology·J B StreisandT H Stanley
Jul 1, 1998·Pharmaceutical Research·J D Eichman, J R Robinson
Nov 1, 2003·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Susanne BredenbergChrister Nyström
May 17, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Joseph A NicolazzoBarrie C Finnin
May 24, 2005·Journal of Pain and Symptom Management·Theodore H Stanley
Dec 24, 2005·Clinical Pharmacokinetics·Mona DarwishJeffrey Thompson
Aug 4, 2006·The Journal of Pain : Official Journal of the American Pain Society·Russell K PortenoySteven Shoemaker
Dec 29, 2006·Journal of Clinical Pharmacology·Mona DarwishJohn G Jiang
Feb 27, 2007·Journal of Clinical Pharmacology·Mona DarwishJohn G Jiang
Aug 24, 2007·Expert Opinion on Pharmacotherapy·M DarwishJ G Jiang
Sep 14, 2010·Journal of Pain and Symptom Management·Robert L Fine

❮ Previous
Next ❯

Citations

Oct 27, 2012·Clinical Pharmacokinetics·Jörn LötschGerd Geisslinger
Nov 1, 2011·Pain Management·Sebastiano Mercadante
May 27, 2015·Pain Practice : the Official Journal of World Institute of Pain·Lucia De FranceschiGabriele Finco
Sep 18, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·R BortolussiD Fantin
Jul 30, 2011·Expert Review of Neurotherapeutics·Mellar P Davis
May 31, 2021·Advanced Drug Delivery Reviews·Zhi LuoJean-Christophe Leroux
Jun 23, 2021·Journal of Pain & Palliative Care Pharmacotherapy·Apoorva Phadke, Purnima Amin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.